Hims & Hers (HIMS) announced the appointment of Kundefinedre Schultz to the company’s board of directors. Schultz spent over 25 years at Novo Nordisk (NVO), where he served in many capacities, most notably as president and COO as the company established itself as a leading company in diabetes care.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HIMS:
- Hims & Hers lower after Capitol Forum uncovers FTC investigation
- Hims & Hers says ‘voluntarily cooperating’ with FTC inquiry, Bloomberg reports
- Hims & Hers says ‘voluntary cooperating’ with FTC inquiry, Bloomberg reports
- Hims & Hers price target raised to $23 from $13 at Truist
- Hims & Hers rises 6.1%